Colorectal Cancer

Colorectal Cancer Quality Measures

Cleveland Clinic is accredited by the National Accreditation Program for Rectal Cancer (NAPRC) which was developed through a collaboration between the OSTRiCh Consortium (Optimizing the Surgical Treatment of Rectal Cancer) and the Commission on Cancer (CoC), a quality program of the American College of Surgeons. The NAPRC's goal is to ensure patients with rectal cancer receive appropriate care using a multidisciplinary approach. NAPRC accreditation signifies demonstration of several rectal cancer care processes and quality metrics that have been proven to improve outcomes.

Quality: At Least 12 Lymph Nodes Removed and Examined Pathologically for Patients Undergoing Resection for Colon Cancer (N = 150)


NCDC = National Cancer Database

ᵃThe National Cancer Database is a nationwide oncology outcomes database and is a joint program of the Commission on Cancer and the American Cancer Society.

Cleveland Clinic's performance was 99.4% (149 of 150 patients; 95% CI, 98.00%-100.00%) in 2018 for this National Cancer Databaseᵃ standard of care quality measure, exceeding the 85% standard performance rate.

Rate of Margin-Free Surgery for Colon and Rectal Cancer (N = 336)


Cleveland Clinic's performance was 93.1% (313 of 336 patients; 95% CI, 90.4%-95.8%) in 2017 for the rate of margin-free surgery for colon and rectal cancer patient.

Percentage of Rectal Cancer Patients Presented at Tumor Boards N = 127)


Cleveland Clinic's performance was 94% (120 of 127 patients; 95% CI, 89.0%-97.8%) in 2018 for rectal cancer patients presented at tumor boards.

Rate of Microsatellite Instability Screening in Colon and Rectal Cancer Patients¹ (N = 341)


Microsatellite instability (MSI) is associated with colon and rectal cancer. Screening for MSI in patients can help to better determine the prognosis of their diagnosis and help identify potential cases of hereditary colorectal cancer syndromes.

¹Includes patients who had their surgery and microsatellite instability screening at Cleveland Clinic as a part of their initial course of treatment.

Cleveland Clinic's performance was 99.4% (339 of 341 patients; 95% CI, 97.9%-99.9%) in 2017 for patients that were screened for Microsatellite Instability.

Median Time to Treatment for Colorectal Cancer Patients


An initial diagnosis of cancer is a time when patients are often desperate for answers.¹ Reducing this stress and anxiety by ensuring patients begin treatment as quickly as possible is a Taussig Cancer Institute imperative. Using the Institute's Cancer Tumor Registry and propriety Cancer Data Warehouse, the difference between the date of first positive biopsy and the first day the patient received any cancer-related treatment is measured quarterly for all patients diagnosed with or treated for cancer at Cleveland Clinic's main campus or family health centers.

After median days to first treatment is calculated for all disease groups, the multidisciplinary teams work to increase access and improve efficiency to reduce the time to treatment. These intensive efforts to identify and solve institutional causes for treatment delays have reduced the median time to treatment initiation.